Imiquimod, pegylated interferon-α-2b and interleukin-2 in the treatment of cutaneous melanoma metastases;Imiquimod, pegyliertes interferon-α-2b und interleukin-2 in der behandlung kutaner melanommetastasen

Hautarzt

Volumn 55, Issue 2, 2004, Pages 176-181

  Loquai, C ^a   Nashan, D ^a   Metze, D ^a   Beiteke, U ^b   Ruping K W ^c   Luger, T A ^a   Grabbe, S ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b KLINIKUM DORTMUND   (Germany)

^c Dermatologische Praxis   (Germany)

Author keywords

Cutaneous melanoma metastases; Imiquimod; Interleukin 2; Pegylated interferon 2b; Topical treatment

Indexed keywords

CYTOKINE; IMIQUIMOD; INTERLEUKIN 2; PEGINTERFERON ALPHA2B;

ARTICLE; CANCER REGRESSION; CREAM; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; MELANOMA; SIDE EFFECT; SKIN FIBROSIS; SKIN INFLAMMATION; SKIN METASTASIS;

ADJUVANTS, IMMUNOLOGIC; AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRALESIONAL; INTERFERON ALFA-2B; INTERFERON INDUCERS; INTERLEUKIN-2; MELANOMA; NEOPLASM METASTASIS; SKIN NEOPLASMS; TIME FACTORS;

EID: 1642333736     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-003-0625-z     Document Type: Article

References (20)

1. Ahmed I, Berth-Jones J (2000) Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 143:843-845
2. Bong AB, Bonnekoh B, Franke I et al. (2002) Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 205:135-138
3. Dahl MV (2002) Imiquimod: a cytokine inducer. J Am Acad Dermatol 47 [Suppl]:205-208
4. Enk AH, Nashan D, Rübben A, Knop J (2000) High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma. Cancer 88:2042-2046
5. Garland SM, Sellors JW, Wikstrom A et al. (2001) Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts-results of an open-label, multicentre Phase IIIB trial. Int J STD AIDS 12:722-729
6. Geisse JK, Rich P, Pandya A et al. (2002) Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 47:390-398
7. Gutwald J, Groth W, Mahrle G (1994) Peritumoral appliziertes IL-2 induziert Tumorregression beim Melanom. Hautarzt 45:536-540
8. Hakansson A, Gustafsson B, Krysander L (1998) Effect of IFN-alfa on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J Interferon Cytokine Res 18:33-39
9. Hengge UR, Stark R (2001) Topical imiquimod to treat intraepidermal carcinoma. Arch Dermatol 137:709-711
10. Miller RL, Birmachu W, Gerster JF (1996) Cytokine induction by imiquimod. Chemother J 5:52-54
11. Moore RA, Edwards JE, Hopwood J, Hicks D (2001) Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis 1:3
12. Oratz R, Hauschild A, Sebastian G et al. (2003) Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma. Melanoma Res 13:59-66
13. Philip RA, Flaherty L (1997) Treatment of malignant melanoma with interleukin-2. Semin Oncol 24:32-38
14. Roberts DL, Anstey AV, Barlow RJ et al. (2002) U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol 146:7-17
15. Singletary SE, Balch CM (1992) Recurrent regional metastases and their management. In: Balch C, Houghton A (eds) Cutaneous melanoma. JB Lippincott, Philadelphia, pp 427-435
16. Steinmann A, Funk JO, Schuler G, von den Driesch P (2000) Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 43:555-556
17. Sterry W, Ruzicka T, Herrera E et al. (2002) Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 147:1227-1236
18. Tefany FJ, Barnetson RS, Halliday GM et al. (1991) Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 97:197-202
19. Von Wussow P, Block B, Hartmann F, Deicher H (1988) Intralesional Interferon-alpha therapy in advanced malignant melanoma. Cancer 61:1071-1074
20. Wolf ICH, Smolle J, Binder B et al. (2003) Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 139:273-276